Efficacy of Tazarotene in Treatment of Verruca Plana

• Status: Not yet recruiting
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Verruca plana is a common skin infection with worldwide distribution. Approximately 10% of general population is infected with flat warts and it represents up to 18 % of the patients seeking treatment for warts. Verruca plana is not merely an infectious disease but also affects the quality of patients' life. Verruca plana causes major cosmetic and social concerns. Lesions' persistence and recurrence cause frustrations and psychological distress which motivate patients to seek different treatment strategies. Verruca plana commonly affects the school aged children which augments its effect on the psychological and social development of children with stigmatization and bullying are great risks. The available treatment strategies neither ensured complete clearance of the disease nor were free of side effects. Frequently used physical removal methods are operator dependent and commonly lead to irritation, local inflammation, scars, dyspigmentation, and disfigurement. In this study we evaluate the efficacy and the safety of tazarotene gel 0.1% in the treatment of verruca plana compared to imiquimod or 5-fluorouracil

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zagazig University
• Treatments: Fluorouracil; Imiquimod; Petrolatum; Tazarotene

Criteria

Inclusion Criteria:

• All participants must be willing to sign informed consent; for patients younger than 18 years old, parents or guardians will sign an informed consent

• Age > 4 years.

• Both sexes.

• Patients with clinically and dermoscopically diagnosed plane warts.

• Subject is willing and able to follow all study instructions and to attend all study visits

Exclusion Criteria:

• • History of hypersensitivity to any of the drugs used.

• Pregnancy and lactation.

• Patients with epidermodysplasia verruciformis syndrome.

• Patients with eczematous skin disorders.

• Presence of any active infections e.g. herpes, tuberculosis.

• History of topical anti wart treatment within 4 weeks of recruitment to the study, and a 12-week period for systemic anti-wart treatment, or immunotherapy, or HPV vaccine in the last 24 weeks.